Therapie der Mycosis fungoides und des Sézary-Syndroms
Adequate therapeutic management of cutaneous T-cell lymphoma (CTCL) requires the identification of the exact CTCL stage and entity within the current WHO classification. There is no curative therapy for CTCL yet, so that treatment currently aims at improving symptoms and quality of life as well as r...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Deutsch |
| Veröffentlicht: |
2. August 2017
|
| In: |
Der Hautarzt
Year: 2017, Jahrgang: 68, Heft: 9, Pages: 702-710 |
| ISSN: | 1432-1173 |
| DOI: | 10.1007/s00105-017-4021-5 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00105-017-4021-5 Verlag, Volltext: https://link.springer.com/article/10.1007/s00105-017-4021-5 
|
| Verfasserangaben: | J.P. Nicolay, C. Assaf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572587814 | ||
| 003 | DE-627 | ||
| 005 | 20220814131239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180503s2017 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-017-4021-5 |2 doi | |
| 035 | |a (DE-627)1572587814 | ||
| 035 | |a (DE-576)502587814 | ||
| 035 | |a (DE-599)BSZ502587814 | ||
| 035 | |a (OCoLC)1341008121 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Nicolay, Jan Peter |d 1981- |e VerfasserIn |0 (DE-588)138614474 |0 (DE-627)604867352 |0 (DE-576)308046188 |4 aut | |
| 245 | 1 | 0 | |a Therapie der Mycosis fungoides und des Sézary-Syndroms |c J.P. Nicolay, C. Assaf |
| 264 | 1 | |c 2. August 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.05.2018 | ||
| 520 | |a Adequate therapeutic management of cutaneous T-cell lymphoma (CTCL) requires the identification of the exact CTCL stage and entity within the current WHO classification. There is no curative therapy for CTCL yet, so that treatment currently aims at improving symptoms and quality of life as well as reducing relapse rates. The treatment has to be stage-adapted. Therapeutic options comprise skin-directed as well as systemic treatment. In early stages, phototherapy and local steroids are the first-line therapeutic options. For the therapy of higher stages, interferon alpha and the RXR-specific retinoid bexarotene are used as first-line medications. Second-line treatment comprises monochemotherapy with agents like gemcitabine or liposomal doxorubicine. Nevertheless, the high relapse rates in higher stages make novel alternative treatment options necessary. As future therapy, especially the fusion protein brentuximab-vedotin directed against CD30 shows promising potential in clinical studies. | ||
| 700 | 1 | |a Assaf, Chalid |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Hautarzt |d Berlin : Springer, 1994 |g 68(2017), 9, Seite 702-710 |h Online-Ressource |w (DE-627)253723752 |w (DE-600)1459162-5 |w (DE-576)072372958 |x 1432-1173 |7 nnas |a Therapie der Mycosis fungoides und des Sézary-Syndroms |
| 773 | 1 | 8 | |g volume:68 |g year:2017 |g number:9 |g pages:702-710 |g extent:9 |a Therapie der Mycosis fungoides und des Sézary-Syndroms |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00105-017-4021-5 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00105-017-4021-5 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180503 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 138614474 |a Nicolay, Jan Peter |m 138614474:Nicolay, Jan Peter |d 60000 |d 61900 |e 60000PN138614474 |e 61900PN138614474 |k 0/60000/ |k 1/60000/61900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1572587814 |e 3007837391 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1572587814","id":{"eki":["1572587814"],"doi":["10.1007/s00105-017-4021-5"]},"title":[{"title_sort":"Therapie der Mycosis fungoides und des Sézary-Syndroms","title":"Therapie der Mycosis fungoides und des Sézary-Syndroms"}],"note":["Gesehen am 03.05.2018"],"person":[{"display":"Nicolay, Jan Peter","role":"aut","given":"Jan Peter","family":"Nicolay","roleDisplay":"VerfasserIn"},{"given":"Chalid","role":"aut","display":"Assaf, Chalid","family":"Assaf","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["J.P. Nicolay, C. Assaf"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"corporate":[{"display":"Deutsche Dermatologische Gesellschaft","role":"isb","roleDisplay":"Herausgebendes Organ"}],"pubHistory":["Volume 45, issue 1 (January 1994) [?]-volume 73, issue 6 (June 2022)"],"recId":"253723752","disp":"Therapie der Mycosis fungoides und des Sézary-SyndromsDer Hautarzt","note":["Gesehen am 05.07.2022","Teils ungezählte Beil.: Supplement"],"id":{"eki":["253723752"],"zdb":["1459162-5"],"issn":["1432-1173"]},"title":[{"title_sort":"Hautarzt","title":"Der Hautarzt","subtitle":"Organ der Deutschen Dermatologischen Gesellschaft"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"702-710","extent":"9","year":"2017","volume":"68","issue":"9","text":"68(2017), 9, Seite 702-710"},"origin":[{"publisher":"Springer","dateIssuedDisp":"[1994?-2022]","publisherPlace":"Berlin ; Heidelberg ; New York"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["ger","eng"]}],"origin":[{"dateIssuedDisp":"2. August 2017","dateIssuedKey":"2017"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["ger"]} | ||
| SRT | |a NICOLAYJANTHERAPIEDE2201 | ||